+91 - 830 - 3146878
The purpose of this study was to evaluvate the efficacy of new herbomineral drug of LAS02 in Prostate cancer patients who admitted in Lavanya Ayurvedic Hospital & Research Centre For Cancer and AIDS. The study was conducted after getting ethical clearance. Total 08 patients were enrolled in Lavanaya hospital. These patients were suffering only from prostate cancer not any other diseases. All patients having medication Ayurvedic herbomineral drug of LAS02 for more than one month treatment. After obtaining prior consent form these patients, venous blood samples was collected from the subjects before and after treatment with herbomineral drug of LAS02 and measured the hematological and biochemical examinations along with Prostate cancer in PSA(prostate specific antigen) Tumor marker. A 81.27% reduction of PSA Tumor marker (ng/ml) in prostate cancer treated patients as compared to before treated patients (n=08) A significant reduction (9.23% ) of ESR levels in patients after treatment with LAS02 more than one month as compared with before treatment. There were significant reduction of hepatic enzymes (SGOT, SGPT, ALP and LDH) levels in patients treated with LAS02 drug in comparison to before treatment. On the basis of these examinations, we say that LAS02 is most effective herbomineral drug for the management of prostate cancer.
The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 08 prostate cancer patients with age (50-90 years) in Lavanya Ayurvedic Hospital and Research Center. These patients were only suffering from prostate cancer patients not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 Capsule under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with in pre and post treated patients.
All hematological and biochemistry parameters hemoglobin (Hb), erythrocyte sedimentation rate (ESR), Albumin, Bilirubin, lactate dehydragenase (LDH) alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) were measured by fully automatic cell counter and clinical chemistry analyzer.
LDH activity was measured by kit according to protocol provided by supplier (Transasia biomedical). The activity was expressed as an IU/ml.
Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treated patients with LAS02 drug in prostate cancer.
There was reduction of 81.27% prostate specific antigen Tumor marker (ng/ml) in prostate cancer post treated patients as compared with pre treated patients. VIEW CHART
SGOT level was significantly decreased and SGPT level was significantly increase but it was found in normal range. In patients after treatment with drug LAS02 in comparison to pre treatment. VIEW CHART
ESR level was significantly decreased 9.23%. In patients after treatment with drug LAS02 in comparison to pre treatment.
Platelets level was significantly decreased 9.62%. In patients after treatment with drug LAS02 in comparison to pre treatment. This parameter was found within normal range. VIEW CHART
There were slightly increased Hb(%) levels. In patient treated group as compared with patient pre treated group. VIEW CHART
The ALP level was significantly decreased 63.33%. In the patients after treatment with drug LAS02 in comparison to pre treatment. VIEW CHART
The LDH level was significantly increased 4.05%. In the patients after treatment with drug LAS02 in comparison to pre treatment. This parameter was found within normal range.
Albumin and Bilirubin level was significantly decreased. In the patients after treatment with drug LAS02 in comparison to pre treatment.
On the basis of these findings it is suggested that the herbomineral drug LAS02 is most effective medicine for prevention of Bone cancer.
The purpose of this study was to evaluate the acute oral toxicity study of LAS02 in female Sprague Dawley rat model. [...]
The purpose of this study was to evaluate the maximum tolerated dose of LAS02 in Sprague dawley female rat. [...]
The aim of this study was to evaluate the maximum tolerated dose of LAS02 in female Sprague Dawley rat. [...]